Peer review Peer review information Nature Reviews Gastroenterology & Hepatology thanks Amedeo Columbano, Simona Rapposelli and the other, anonymous, reviewer(s) for their contribution to the peer review of this work
Potential Cardiovascular Benefits: Some GLP-1 agonists, such as semaglutide, have shown to reduce the risk of major cardiovascular events (e.g., heart attacks, strokes), particularly in patients with type 2 diabetes
Peptide Vials (CJC-1295 DAC, 2 mg each): 8 weeks: 8 vials (1 vial/week) 12 weeks: 12 vials (1 vial/week) Insulin Syringes (U-100, 1 mL capacity): Per week: 1 syringe 8 weeks: 8 syringes 12 weeks: 12 syringes Bacteriostatic Water (10 mL bottles): Use 1.0 mL per vial for reconstitution
It is not approved for human or veterinary therapeutic use, self-administration, or any clinical application
Boost energy, reduce inflammation, and enhance recovery
June 1, 2026: More Lawsuits Filed in GLP-1 Litigation as Eli Lilly Asks for Lawsuit Dismissal The company that makes Trulicity, Eli Lilly, has asked for lawsuits in the GLP-1 to be dismissed and asked for testimonies from plaintiffs experts to be excluded
